Biomarkers in Predicting Response in Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Treated on GOG-0172 or GOG-0182

ERCC1 Expression as a Predictor of Progression Free and Overall Survival in Patients With Epithelial Ovarian Cancer Treated on GOG Protocols 0172 and 0182

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01074398

Enrollment

513

Registered

2010-02-24

Start date

2010-02-28

Completion date

Unknown

Last updated

2010-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer

Keywords

recurrent ovarian epithelial cancer, stage III ovarian epithelial cancer, stage IV ovarian epithelial cancer, fallopian tube cancer, peritoneal cavity cancer

Brief summary

RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how well patients will respond to treatment. PURPOSE: This research study is looking at biomarkers in predicting response in patients with advanced ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.

Detailed description

OBJECTIVES: Primary * To evaluate ERCC1 tumor expression, as measured by IHC, as a predictor of progression-free and overall survival of patients with advanced ovarian epithelial cancer. Secondary * To correlate ERCC1 single-nucleotide polymorphisms (C8092A and codon 118) with ERCC1 tumor expression. OUTLINE: This is a multicenter study. Blood and paraffin-embedded tumor tissue samples are analyzed for ERCC1 tumor expression by IHC and single-nucleotide polymorphisms.

Interventions

GENETICgene expression analysis

GENETICpolymorphism analysis

GENETICprotein expression analysis

OTHERimmunohistochemistry staining method

OTHERlaboratory biomarker analysis

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

DISEASE CHARACTERISTICS: * Histologically confirmed advanced invasive ovarian epithelial carcinoma, fallopian tube adenocarcinoma, or primary peritoneal carcinoma * Has undergone optimal surgical staging * Has received chemotherapy on either GOG-0172 or GOG-0182 * Adequate blood or DNA available for ERCC1 analysis * Adequate tumor on paraffin-embedded tissue for IHC staining PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * See Disease Characteristics

Design outcomes

Primary

Measure	Time frame
Association between ERCC1 tumor expression and progression-free and overall survival	—

Secondary

Measure	Time frame
Association between ERCC1 polymorphisms and ERCC1 tumor expression	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026